These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 31658862)
1. Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints. Damghani T; Mashayekh K; Pirhadi S; Firuzi O; Sharifi S; Edraki N; Khoshneviszadeh M; Avestan MS J Recept Signal Transduct Res; 2019 Aug; 39(4):295-303. PubMed ID: 31658862 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors. Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors. Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors. Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792 [TBL] [Abstract][Full Text] [Related]
11. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study. Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors. Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010 [TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors. Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784 [TBL] [Abstract][Full Text] [Related]
15. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors. El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754 [TBL] [Abstract][Full Text] [Related]
16. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity. Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors. Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091 [TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]